Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Alkermes' schizophrenia candidate Aristada featured in Phase 3b published study » 07:06
05/20/20
05/20
07:06
05/20/20
07:06
ALKS

Alkermes

$16.16 /

-0.32 (-1.94%)

Alkermes announced that…

Alkermes announced that data from its phase 3b ALPINE study were published in the Journal of Clinical Psychiatry. ALPINE was a six-month study evaluating the efficacy and safety of the Aristada Initio one-day initiation regimen, consisting of Aristada Initio and one single dose of 30 mg of oral aripiprazole, together with the Aristada two-month dose in patients experiencing an acute exacerbation of schizophrenia. Positive topline data were first reported in April 2019. Results from the study provide evidence to support the use of the Aristada Initio one-day regimen together with Aristada for treatment of an acute exacerbation of schizophrenia, started in the hospital setting and continued through the critical transition to outpatient care. ALPINE was a multi-center, randomized, double-blind, phase 3b study designed to examine the efficacy and safety of using either Aristada or Invega Sustenna to start treatment in hospitalized patients experiencing an acute exacerbation of schizophrenia and continue them on treatment during the transition to outpatient care for ongoing continuation phase therapy.

ShowHide Related Items >><<
ALKS Alkermes
$16.16 /

-0.32 (-1.94%)

ALKS Alkermes
$16.16 /

-0.32 (-1.94%)

04/30/20 H.C. Wainwright
Alkermes price target lowered to $23 from $25 at H.C. Wainwright
04/29/20 Piper Sandler
Alkermes price target lowered to $21 from $22 at Piper Sandler
04/29/20 Stifel
Alkermes price target lowered to $17 from $20 at Stifel
02/14/20 JPMorgan
JPMorgan downgrades Alkermes to Neutral into 'relatively quiet' 2020
ALKS Alkermes
$16.16 /

-0.32 (-1.94%)

ALKS Alkermes
$16.16 /

-0.32 (-1.94%)

ALKS Alkermes
$16.16 /

-0.32 (-1.94%)

Over a week ago
Hot Stocks
Alkermes presents new data from schizophrenia portfolio at virtual SIRS congress » 07:19
05/14/20
05/14
07:19
05/14/20
07:19
ALKS

Alkermes

$15.42 /

-0.18 (-1.15%)

Alkermes presented new…

Alkermes presented new data from its schizophrenia portfolio as part of the virtual 2020 Congress of the Schizophrenia International Research Society, or SIRS. New e-posters related to ALKS 3831, Aristada and epidemiological schizophrenia data are now posted on the SIRS website, including: results from the completed ENLIGHTEN-2-extension study evaluating the safety and tolerability of ALKS 3831 in patients with schizophrenia who completed the phase 3, 24-week ENLIGHTEN-2 study; data from an exploratory analysis for ARISTADA evaluating the feasibility and utility of wrist actigraphy to measure key activity and sleep parameters; findings from a retrospective cross-sectional analysis examining disease prevalence, comorbid conditions, and medication utilization in a large population of commercially- or Medicaid-insured individuals diagnosed with schizophrenia in the U.S. to characterize this patient population.

ShowHide Related Items >><<
ALKS Alkermes
$15.42 /

-0.18 (-1.15%)

ALKS Alkermes
$15.42 /

-0.18 (-1.15%)

04/30/20 H.C. Wainwright
Alkermes price target lowered to $23 from $25 at H.C. Wainwright
04/29/20 Piper Sandler
Alkermes price target lowered to $21 from $22 at Piper Sandler
04/29/20 Stifel
Alkermes price target lowered to $17 from $20 at Stifel
02/14/20 JPMorgan
JPMorgan downgrades Alkermes to Neutral into 'relatively quiet' 2020
ALKS Alkermes
$15.42 /

-0.18 (-1.15%)

ALKS Alkermes
$15.42 /

-0.18 (-1.15%)

ALKS Alkermes
$15.42 /

-0.18 (-1.15%)

Hot Stocks
Alkermes expands patient access to Aristada, Vivitrol during COVID-19 pandemic » 07:40
05/11/20
05/11
07:40
05/11/20
07:40
ALKS

Alkermes

$15.00 /

+0.34 (+2.32%)

Alkermes announced the…

Alkermes announced the expansion of several programs and services in support of patient access to its proprietary medicines during the COVID-19 crisis. During this unprecedented and rapidly evolving situation, the company remains focused on helping to assure that patients have uninterrupted access to Aristada, an injectable atypical antipsychotic for the treatment of schizophrenia in adults, and Vivitrol, indicated for the treatment of alcohol dependence and the prevention of relapse to opioid dependence following opioid detoxification. The company is expanding its injection site network to include additional appropriate retail pharmacies and clinics where patients can receive injections of Aristada and Vivitrol. As part of this initiative, Alkermes has added to its provider locator more than 900 on-site retail pharmacies. Pharmacists at designated Albertsons locations throughout the U.S. now are available to provide injections of Aristada and Vivitrol. These Albertsons sites extend Alkermes' existing provider locator network and offer patients additional injection options across the country.

ShowHide Related Items >><<
ALKS Alkermes
$15.00 /

+0.34 (+2.32%)

04/30/20 H.C. Wainwright
Alkermes price target lowered to $23 from $25 at H.C. Wainwright
04/29/20 Piper Sandler
Alkermes price target lowered to $21 from $22 at Piper Sandler
04/29/20 Stifel
Alkermes price target lowered to $17 from $20 at Stifel
02/14/20 JPMorgan
JPMorgan downgrades Alkermes to Neutral into 'relatively quiet' 2020
Recommendations
Alkermes price target lowered to $23 from $25 at H.C. Wainwright » 07:14
04/30/20
04/30
07:14
04/30/20
07:14
ALKS

Alkermes

$14.40 /

-1.63 (-10.17%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Douglas Tsao lowered the firm's price target on Alkermes to $23 from $25 and reiterates a Neutral rating on the shares. The company reported "solid" Q1 earnings though its guidance withdrawn as COVID-19 creates uncertainty, Tsao tells investors in a research note.

ShowHide Related Items >><<
ALKS Alkermes
$14.40 /

-1.63 (-10.17%)

04/29/20 Piper Sandler
Alkermes price target lowered to $21 from $22 at Piper Sandler
04/29/20 Stifel
Alkermes price target lowered to $17 from $20 at Stifel
02/14/20 JPMorgan
JPMorgan downgrades Alkermes to Neutral into 'relatively quiet' 2020
02/14/20 H.C. Wainwright
Alkermes profitability focus 'underwhelms' for 2020, says H.C. Wainwright
Recommendations
Alkermes price target lowered to $21 from $22 at Piper Sandler » 12:37
04/29/20
04/29
12:37
04/29/20
12:37
ALKS

Alkermes

$14.62 /

-1.41 (-8.80%)

Piper Sandler analyst…

Piper Sandler analyst Danielle Brill lowered the firm's price target on Alkermes to $21 from $22 and keeps a Neutral rating on the shares after the company reported Q1 results and withdrew its guidance for 2020. Brill said that she remains concerned about Alkermes' pipeline needs and now its current product franchise is facing coronavirus-related headwinds. The analyst added that she lowered her revenue estimates to reflect the current reported trends throughout Q2, with some recovery in the back end of 2020. Brill also noted that an Ad Comm panel is expected for LKS-3831, adding further uncertainty to the future revenue outlook.

ShowHide Related Items >><<
ALKS Alkermes
$14.62 /

-1.41 (-8.80%)

04/29/20 Stifel
Alkermes price target lowered to $17 from $20 at Stifel
02/14/20 JPMorgan
JPMorgan downgrades Alkermes to Neutral into 'relatively quiet' 2020
02/14/20 H.C. Wainwright
Alkermes profitability focus 'underwhelms' for 2020, says H.C. Wainwright
02/14/20 BofA
Alkermes downgraded to Neutral from Buy at BofA
Recommendations
Alkermes price target lowered to $17 from $20 at Stifel » 12:25
04/29/20
04/29
12:25
04/29/20
12:25
ALKS

Alkermes

/

+

Stifel analyst Paul…

Stifel analyst Paul Matteis lowered the firm's price target on Alkermes to $17 from $20 and keeps a Hold rating on the shares. The company withdrawing 2020 guidance confirms that Vivitrol and Aristada, along with long-acting injectable royalties, are likely more sensitive than the average biotech drug to pandemic-related behavioral changes, Matteis tells investors in a post-earnings research note. While Alkermes' Q1 results were "quite strong," there are reasons to be concerned that both Vivitrol and Aristada may come under pressure that could last beyond Q2, contends the analyst.

ShowHide Related Items >><<
ALKS Alkermes
/

+

02/14/20 JPMorgan
JPMorgan downgrades Alkermes to Neutral into 'relatively quiet' 2020
02/14/20 H.C. Wainwright
Alkermes profitability focus 'underwhelms' for 2020, says H.C. Wainwright
02/14/20 BofA
Alkermes downgraded to Neutral from Buy at BofA
02/14/20 BofA
Alkermes downgraded to Neutral from Buy at BofA
Earnings
Alkermes withdraws previous FY20 guidance due to COVID-19 impact » 07:05
04/29/20
04/29
07:05
04/29/20
07:05
ALKS

Alkermes

$16.03 /

-0.47 (-2.85%)

Due to uncertainties…

Due to uncertainties regarding the impact of the COVID-19 pandemic on Alkermes' operating and financial results, Alkermes withdraws the financial expectations for 2020 set forth in its press release dated Feb. 13, 2020. The company expects that the extent of the impact of COVID-19 on its business will be driven primarily by the severity and duration of the pandemic. While the company has adopted practices to mitigate the impact of COVID-19 disruptions, at this time, it is unable to reasonably estimate the impact of the pandemic on future results.

ShowHide Related Items >><<
ALKS Alkermes
$16.03 /

-0.47 (-2.85%)

02/14/20 JPMorgan
JPMorgan downgrades Alkermes to Neutral into 'relatively quiet' 2020
02/14/20 H.C. Wainwright
Alkermes profitability focus 'underwhelms' for 2020, says H.C. Wainwright
02/14/20 BofA
Alkermes downgraded to Neutral from Buy at BofA
02/14/20 BofA
Alkermes downgraded to Neutral from Buy at BofA
Earnings
Alkermes reports Q1 adjusted EPS 1c, consensus (6c) » 07:04
04/29/20
04/29
07:04
04/29/20
07:04
ALKS

Alkermes

$16.03 /

-0.47 (-2.85%)

Reports Q1 revenue…

Reports Q1 revenue $246.2M, consensus $228.23M.

ShowHide Related Items >><<
ALKS Alkermes
$16.03 /

-0.47 (-2.85%)

02/14/20 JPMorgan
JPMorgan downgrades Alkermes to Neutral into 'relatively quiet' 2020
02/14/20 H.C. Wainwright
Alkermes profitability focus 'underwhelms' for 2020, says H.C. Wainwright
02/14/20 BofA
Alkermes downgraded to Neutral from Buy at BofA
02/14/20 BofA
Alkermes downgraded to Neutral from Buy at BofA
Over a month ago
Hot Stocks
Alkermes' candidate ALKS 4230 shows anti-tumor efficacy in publication » 07:05
04/22/20
04/22
07:05
04/22/20
07:05
ALKS

Alkermes

$16.23 /

-0.39 (-2.35%)

Alkermes announced the…

Alkermes announced the publication of preclinical data demonstrating the selectivity and anti-tumor efficacy of its investigational, immunotherapy candidate, ALKS 4230, in the Journal for ImmunoTherapy of Cancer. ALKS 4230, a novel cytokine, is an investigational, engineered fusion protein designed to selectively expand tumor-killing immune cells while avoiding the interleukin-2-induced activation of immunosuppressive cells. The data demonstrated that ALKS 4230 selectively activated the intermediate-affinity IL-2 receptor as intended. Additionally, data from a mouse B6F10 lung metastasis model demonstrated that treatment with ALKS 4230 achieved a maximum of 100% inhibition of tumor growth with one of the doses tested, as compared to treatment with recombinant human IL-2, which achieved a maximum of 70% inhibition of tumor growth with one of the doses tested. In this model, equivalent anti-tumor activity of ALKS 4230 was observed whether it was administered intravenously or subcutaneously. ALKS 4230 treatment of peripheral blood mononuclear cells (PBMCs) from patients with melanoma or renal cell carcinoma resulted in the selective expansion of CD8+ T cells and NK cells with negligible effects on Treg expansion. ALKS 4230 showed superior anti-tumor efficacy to rhIL-2 in a mouse B6F10 lung metastasis model and the ability to achieve equivalent anti-tumor efficacy when administered either intravenously or subcutaneously. ALKS 4230 is currently being studied in both monotherapy and combination settings as part of the Alkermes-sponsored ARTISTRY clinical development program.

ShowHide Related Items >><<
ALKS Alkermes
$16.23 /

-0.39 (-2.35%)

02/14/20 JPMorgan
JPMorgan downgrades Alkermes to Neutral into 'relatively quiet' 2020
02/14/20 H.C. Wainwright
Alkermes profitability focus 'underwhelms' for 2020, says H.C. Wainwright
02/14/20 BofA
Alkermes downgraded to Neutral from Buy at BofA
02/14/20 BofA
Alkermes downgraded to Neutral from Buy at BofA
Conference/Events
Eyeforpharma to hold a virtual conference » 07:53
04/15/20
04/15
07:53
04/15/20
07:53
ABBV

AbbVie

$82.12 /

+4.07 (+5.21%)

, ABEO

Abeona Therapeutics

$2.59 /

+0.175 (+7.25%)

, ALKS

Alkermes

$15.55 /

+0.17 (+1.11%)

, AMGN

Amgen

$226.75 /

+8.46 (+3.88%)

, AMRN

Amarin

$6.38 /

+ (+0.00%)

, AZN

AstraZeneca

$48.71 /

+1.29 (+2.72%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BIIB

Biogen

$333.55 /

+10.7 (+3.31%)

, CRM

Salesforce

$157.79 /

+5.27 (+3.46%)

, DIS

Disney

$106.00 /

+2.45 (+2.37%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, FB

Facebook

$177.92 /

+3.05 (+1.74%)

, GSK

GlaxoSmithKline

$40.38 /

+1.45 (+3.72%)

, GTHX

G1 Therapeutics

$13.08 /

+0.75 (+6.08%)

, LLY

Eli Lilly

$151.17 /

+6.81 (+4.72%)

, MNK

Mallinckrodt

$3.92 /

+0.175 (+4.67%)

, MRK

Merck

$82.86 /

+2.33 (+2.89%)

, MSFT

Microsoft

$173.70 /

+8.19 (+4.95%)

, NVO

Novo Nordisk

$59.81 /

+1.03 (+1.75%)

, NVS

Novartis

$86.25 /

+2.03 (+2.41%)

, OTSKY

Otsuka

$0.00 /

+ (+0.00%)

, PFE

Pfizer

$36.44 /

+1.29 (+3.67%)

, SEPR

Sepracor

$0.00 /

+ (+0.00%)

, SGEN

Seattle Genetics

$123.79 /

+3.77 (+3.14%)

, SNY

Sanofi

$45.96 /

+1.57 (+3.54%)

, SYNH

Syneos Health

$49.67 /

+2.12 (+4.46%)

, TAK

Takeda Pharmaceutical

$16.88 /

+0.18 (+1.08%)

Eyeforpharma Philadelphia…

Eyeforpharma Philadelphia will be held virtually on April 14-17 with webcasts starting at 9 am each day. Webcast Link

ShowHide Related Items >><<
ABBV AbbVie
$82.12 /

+4.07 (+5.21%)

03/30/20 Piper Sandler
CytomX Therapeutics payment for CX-2029 notable milestone, says Piper Sandler
03/26/20 Piper Sandler
Doctor survey shows 'massive' near-term COVID disruption, says Piper Sandler
03/24/20 Wedbush
CytomX Therapeutics upgraded to Outperform at Wedbush
03/23/20 Societe Generale
AbbVie downgraded to Hold from Buy at Societe Generale
ABEO Abeona Therapeutics
$2.59 /

+0.175 (+7.25%)

12/30/19 H.C. Wainwright
Abeona Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
12/20/19 Cantor Fitzgerald
Abeona financing to lessen takeover chartter, says Cantor Fitzgerald
12/10/19 Cantor Fitzgerald
Abeona Therapeutics assumed with a Neutral at Cantor Fitzgerald
08/15/19
Fly Intel: Top five analyst downgrades
ALKS Alkermes
$15.55 /

+0.17 (+1.11%)

02/14/20 JPMorgan
JPMorgan downgrades Alkermes to Neutral into 'relatively quiet' 2020
02/14/20 H.C. Wainwright
Alkermes profitability focus 'underwhelms' for 2020, says H.C. Wainwright
02/14/20 BofA
Alkermes downgraded to Neutral from Buy at BofA
02/14/20 BofA
Alkermes downgraded to Neutral from Buy at BofA
AMGN Amgen
$226.75 /

+8.46 (+3.88%)

04/13/20 Citi
Sharp drop in chemo use negative for Amgen and Coherus, says Citi
03/31/20 Wolfe Research
Amgen initiated with a Peer Perform at Wolfe Research
03/30/20
Fly Intel: Top five analyst upgrades
03/29/20 Raymond James
Raymond James upgrades Amgen to Outperform on limited COVID-19 disruption
AMRN Amarin
$6.38 /

+ (+0.00%)

04/14/20 Roth Capital
Amarin gearing up to push back against ANDA filers ruling, says Roth Capital
04/14/20 Cowen
Amarin price target raised to $10 from $8 at Cowen
04/14/20 Stifel
Amarin 2020 view 'sufficiently conservative' to still be achievable, says Stifel
04/14/20 Jefferies
Amarin's Vascepa launch continues to be one of best in biotech, says Jefferies
AZN AstraZeneca
$48.71 /

+1.29 (+2.72%)

04/13/20 B. Riley FBR
AstraZeneca study halt has positive read-through to Fortress, says B. Riley FBR
02/28/20 Cowen
AstaZeneca pipeline leads to best European idea, says Cowen
01/27/20 William Blair
PhaseBio could see increase to PB2452 addressable market, says William Blair
01/22/20 Liberum
Sanofi downgraded to Hold from Buy at Liberum (earlier)
BAYRY Bayer
$0.00 /

+ (+0.00%)

03/13/20 Goldman Sachs
Bayer price target lowered to EUR 76 from EUR 77 at Goldman Sachs
03/11/20 Deutsche Bank
Deutsche Bank names Bayer as 'Catalyst Call' buy idea
03/04/20 Deutsche Bank
Bayer upgraded to Buy from Hold at Deutsche Bank
12/19/19 BofA
Elanco upgraded to Buy from Neutral at BofA/Merrill
BIIB Biogen
$333.55 /

+10.7 (+3.31%)

03/31/20 Wolfe Research
Biogen initiated with a Peer Perform at Wolfe Research
03/13/20 Jefferies
Large-cap biotech remains good 'defensive zone' for 2020, says Jefferies
02/28/20 William Blair
Biogen deal with Sangamo unlikely to have near-term impact, says William Blair
CRM Salesforce
$157.79 /

+5.27 (+3.46%)

04/01/20 Wedbush
Salesforce removed from Best Ideas List at Wedbush
03/24/20 Wedbush
Microsoft, Alphabet among stocks in Wedbush's Shopping List
03/20/20 Cowen
Salesforce reiterated as a Best idea at Cowen
02/27/20 RBC Capital
Former Salesforce co-CEO Block could end up at Workday, Oracle, says RBC Capital
DIS Disney
$106.00 /

+2.45 (+2.37%)

04/14/20 SunTrust
Roku price target lowered to $110 from $160 at SunTrust
04/14/20 Credit Suisse
Cogent price target raised to $99 from $86 at Credit Suisse
04/13/20 Cowen
Glu Mobile weakness a buying opportunity, says Cowen
04/09/20 Rosenblatt
Disney+ could reach almost 70M subscribers by end of June, says Rosenblatt
ESALY Eisai
$0.00 /

+ (+0.00%)

10/24/19 Nomura Instinet
Eisai upgraded to Buy from Neutral at Nomura Instinet
09/24/19 Jefferies
Eisai initiated with a Buy at Jefferies
09/17/19 Daiwa
Eisai downgraded to Sell from Neutral at Daiwa
08/05/19 Citi
Eisai upgraded to Neutral from Sell at Citi
FB Facebook
$177.92 /

+3.05 (+1.74%)

04/09/20 Loop Capital
Facebook price target lowered to $215 from $245 at Loop Capital
04/08/20 Deutsche Bank
Pinterest update shows Snap could post in-line Q1, says Deutsche Bank
04/07/20 Barclays
Facebook price target lowered to $175 from $260 at Barclays
04/02/20 Rosenblatt
Rosenblatt cuts advertising estimates, says Facebook/Roku/Snap show best upside
GSK GlaxoSmithKline
$40.38 /

+1.45 (+3.72%)

03/11/20 JPMorgan
JPMorgan backs Neutral on GSK after 2019 annual report
01/16/20 Barclays
GlaxoSmithKline downgraded to Underweight from Equal Weight at Barclays
12/16/19 Goldman Sachs
BioMarin, Regeneron among Goldman's six Healthcare 'laggards' for 2020
12/03/19 Morgan Stanley
Morgan Stanley sees high odds of Bluebird trading up after multiple myeloma data
GTHX G1 Therapeutics
$13.08 /

+0.75 (+6.08%)

02/27/20 Wedbush
G1 Therapeutics price target lowered to $55 from $67 at Wedbush
01/21/20 H.C. Wainwright
G1 Therapeutics price target raised to $82 from $72 at H.C. Wainwright
01/07/20 BTIG
G1 Therapeutics price target lowered to $51 from $80 at BTIG
08/08/19 JPMorgan
G1 Therapeutics upgraded to Overweight from Neutral at JPMorgan
LLY Eli Lilly
$151.17 /

+6.81 (+4.72%)

04/09/20 Morgan Stanley
Morgan Stanley downgrades Eli Lilly to Equal Weight with premium near prior peak
04/09/20 Morgan Stanley
Eli Lilly downgraded to Equal Weight from Overweight at Morgan Stanley
03/11/20
Fly Intel: Top five analyst upgrades
03/11/20 Goldman Sachs
Eli Lilly upgraded to Conviction Buy from Buy at Goldman Sachs
MNK Mallinckrodt
$3.92 /

+0.175 (+4.67%)

02/25/20 Stifel
Mallinckrodt clearing path for shares to be revalued, says Stifel
01/22/20 Wells Fargo
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo
09/10/19 Stifel
Mallinckrodt's sale of BioVectra helps alleviate cash pressure, says Stifel
09/09/19 Stifel
Mallinckrodt price target lowered to $8 from $20 at Stifel
MRK Merck
$82.86 /

+2.33 (+2.89%)

04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/23/20 Mizuho
Merck business disruptions have been modest, says Mizuho
03/02/20 William Blair
Merck results revive fears about Seattle Genetics' Adcetris, says William Blair
02/27/20 Barclays
Merck initiated with an Overweight at Barclays
MSFT Microsoft
$173.70 /

+8.19 (+4.95%)

04/15/20 BofA
Microsoft estimates trimmed after reseller checks at BofA
04/02/20 Piper Sandler
RingCentral videoconference product launch negative for Zoom, says Piper Sandler
03/31/20 Citi
Microsoft price target lowered to $167 from $170 at Citi
03/26/20 Baird
Bandwidth added as a Fresh Pick at Baird
NVO Novo Nordisk
$59.81 /

+1.03 (+1.75%)

03/23/20 UBS
Novo Nordisk upgraded to Buy from Neutral at UBS
03/16/20 BofA
Novo Nordisk upgraded to Buy from Neutral at BofA
01/03/20 Guggenheim
Novo Nordisk downgraded to Neutral on continued insulin headwinds at Guggenheim
01/03/20 Guggenheim
Novo Nordisk downgraded to Neutral from Buy at Guggenheim
NVS Novartis
$86.25 /

+2.03 (+2.41%)

03/26/20 Argus
Alcon upgraded to Buy from Hold at Argus
03/11/20 Morgan Stanley
Novartis upgraded to Equal Weight yesterday at Morgan Stanley
03/10/20 H.C. Wainwright
Novartis' recent R&D day driving interest in Xoma, says H.C. Wainwright
03/10/20 Morgan Stanley
Novartis upgraded to Equal Weight from Underweight at Morgan Stanley
OTSKY Otsuka
$0.00 /

+ (+0.00%)

03/26/20 Citi
Otsuka upgraded to Buy from Neutral at Citi
03/24/20 JPMorgan
Otsuka upgraded to Neutral from Underweight at JPMorgan
12/26/19 Mizuho
Otsuka downgraded to Neutral from Buy at Mizuho
12/09/19 Jefferies
Otsuka initiated with a Buy at Jefferies
PFE Pfizer
$36.44 /

+1.29 (+3.67%)

04/03/20 Canaccord
BioNTech price target raised to $60 from $22 at Canaccord
03/25/20 Piper Sandler
Piper Sandler sees FY20 U.S. sales of Opko's Rayaldee at $52.5M
02/27/20 Standpoint Research
Pfizer upgraded to Buy from Hold at Standpoint Research
02/27/20 Barclays
Pfizer initiated with an Equal Weight at Barclays
SEPR Sepracor
$0.00 /

+ (+0.00%)

SGEN Seattle Genetics
$123.79 /

+3.77 (+3.14%)

04/03/20 Stifel
Stifel says Seattle Genetics FDA talks on EV positive, but not surprising
02/18/20 Barclays
Seattle Genetics downgraded to Equal Weight from Overweight at Barclays
02/18/20 Barclays
Seattle Genetics downgraded to Equal Weight from Overweight at Barclays
SNY Sanofi
$45.96 /

+1.57 (+3.54%)

03/27/20 Roth Capital
Roth Capital highlights Translate Bio's scalable mRNA platform
03/17/20 Barclays
Sanofi upgraded to Equal Weight from Underweight at Barclays
03/11/20 Oppenheimer
Regeneron price target raised to $525 from $450 at Oppenheimer
03/10/20 Goldman Sachs
Sanofi upgraded to Buy from Neutral at Goldman Sachs
SYNH Syneos Health
$49.67 /

+2.12 (+4.46%)

04/03/20 Mizuho
Syneos Health price target lowered to $42 from $56 at Mizuho
04/02/20 Credit Suisse
Syneos Health price target lowered to $62 from $72 at Credit Suisse
03/30/20 Goldman Sachs
Syneos Health downgraded to Neutral from Buy at Goldman Sachs
03/17/20 SunTrust
SunTrust cuts price targets across CROs, downgrades MedPace
TAK Takeda Pharmaceutical
$16.88 /

+0.18 (+1.08%)

03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
03/25/20 Stifel
Molecular Templates initiated with a Buy at Stifel
02/25/20 Stifel
Iovance among 'more interesting' cell therapy takeout candidates, says Stifel
02/12/20 Wells Fargo
Fate Therapeutics price target raised to $34 from $24 at Wells Fargo

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.